SYK·Stryker Corporation

Stryker Corporation is a global medical technology company specializing in innovative solutions for healthcare professionals across its MedSurg and Neurotechnology, and Orthopaedics segments. The company provides a wide array of products, including surgical equipment, neurotechnology devices, implants for joint replacements and trauma, and spinal systems, distributed in approximately 75 countries. Stryker operates within the Healthcare sector, specifically the Medical Devices industry, focusing on advancing patient care through its technological offerings. Stryker has demonstrated a consistent pattern of exceeding analyst estimates for both earnings per share (EPS) and revenue in recent quarters. For Q1 2026, the company reported actual EPS of $2.60 against an estimate of $2.98 and actual revenue of $6.02 billion versus an estimate of $6.33 billion, marking a miss on both metrics. However, prior to this, the company had a strong track record. In Q4 2025, actual EPS was $4.47 versus an estimate of $4.44, and actual revenue was $7.17 billion against an estimate of $7.19 billion. Looking further back, Q3 2025 saw actual EPS of $3.19 against an estimate of $3.13, Q2 2025 had actual EPS of $3.13 against an estimate of $3.07, and Q1 2025 reported actual EPS of $2.84 versus an estimate of $2.73. Stryker has a notable history of beating analyst estimates, particularly in EPS, with a streak of positive surprises in Q1 2025, Q2 2025, Q3 2025, and Q4 2025. The company also managed to meet revenue estimates in Q4 2025. The most recent quarter, Q1 2026, however, presented a deviation from this trend with misses in both EPS and revenue. This recent miss breaks a prior pattern of consistent beats, making the upcoming performance crucial for assessing its return to form. Recent news highlights significant strategic moves by Stryker. The company finalized its acquisition of Amplitude Vascular Systems, integrating next-generation intravascular lithotripsy (IVL) technology to bolster its peripheral vascular portfolio and compete in a growing market. Additionally, Stryker's Board declared a quarterly dividend of $0.88 per share, a 4.8% increase year-over-year, signaling confidence in its financial stability and commitment to shareholder returns. It was also noted that reported profits were reduced by $684 million due to unusual items over the past year, suggesting potential for improved future profitability if these are non-recurring. Moving forward, investors will be closely monitoring Stryker's integration of the Amplitude Vascular Systems IVL technology and its impact on the peripheral vascular segment. Key will be whether the company can return to its historical pattern of exceeding EPS and revenue estimates, especially following the recent Q1 2026 miss, and the extent to which the unusual items impacting past profits prove to be non-recurring.